Market-Moving News for June 21st
Market-Moving News for June 21st
SRPT: 45% | Sarepeta Therapeutics shares are trading higher after the company announced FDA approval of an expansion to the labeled indication for ELEVIDYS to include individuals with Duchenne muscular dystrophy with a confirmed mutation in the DMD gene who are at least 4 years of age. Also, multiple firms raised their respective price targets on the stock.
SRPT：45% | 瑞普塔治療股價上漲，該公司宣佈FDA批准將ELEVIDYS的標籤適應症擴展至Duchenne肌無力患者，這些患者年齡至少爲4歲並確認DMD基因存在突變。此外，多家公司將其股票價格目標上調。
CLOV: 13% | Clover Health shares are trading higher following the purchase of 877,567 shares by a company director.
CLOV：13% | Clover Health的股價上漲，一位董事購買了877，567股。
NVNO: 16% | EnVVeno Medical shares are trading higher after the company reported interim venous ulcer healing data from the SAVVE U.E. pivotal trial for VenoValve, which will be presented at the Society for Vascular Surgery 2024 Annual Meeting.
NVNO: 16% | EnVVeno Medical的股價上漲，該公司報告了VenoValve的SAVVE UE關鍵試驗中間期靜脈潰瘍癒合數據，將在2024年血管外科學會年會上展示。
譯文內容由第三人軟體翻譯。
